By virtue of the uncovered role of SphK1 in mediating the transition from androgen-dependent to androgen refractory state, the pharmacological inhibition of SphK1 and its downstream signaling could represent a viable strategy to prevent or delay the progression to hormone-refractory prostate cancer. Here, SPHK1 is linked to prostate carcinoma.